A flat price with the bands printed
Each molecule carries one figure and then a list of the dose bands it applies to, six apiece. That is the difference between a claim and a disclosure: a reader can see the top of the range the price is promised to cover.
The page also states that nothing changes as treatment progresses, which is the specific claim a dose-escalation surcharge would break.
No company, and a letter about claims
The only corporate-form string on the pages we read is a footer navigation label, which is a documented false positive and was rejected in context. The copyright line carries the brand and no corporate form.
Its homepage renders barely two thousand characters, so the priced page is one click in with little to lead a reader there.
FDA issued a warning letter in February 2026 over false and misleading claims. Per this site’s standing rule, that discloses; it does not disqualify and moves no score here.
PharmaZee's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $99/mo"Compound Semaglutide · BEST VALUE · As low as $99 /mo · Same price for all doses. 0.25 mg | .5 mg | 1 mg | 1.5 mg | 2 mg | 2.5 mg" | September 2026source |
| Tirzepatide (compounded) | $149/mo"Compound Tirzepatide · MOST EFFECTIVE · As low as $149 /mo · Same price for all doses. 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg" | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 240 providers reviewed here are paid partners today; the other 236 are not. See how this works.
See PharmaZee's current price →Good fit if
- Buyers who want a flat price with the dose bands it covers printed beside it.
- Readers who want both molecules priced on one page without an intake.
- People who want a stated per-month unit rather than a blank one.
Look elsewhere if
- Anyone who wants the operating company named.
- Readers who need the membership question answered.
- Buyers who want a named pharmacy or clinician.
- People who need a service-area list.
How this review was verified
- Re-read the homepage and the GLP-1 medications page on 7 September 2026, comparing requested to effective URLs with a nonsense path against the host in the same run, which returned a 404.
- Recorded the dose bands the flat price covers, as printed, rather than the seller’s summary of them.
- Read the single corporate-form hit in context, established it is a navigation label, and rejected it.
- Screened an exact phrase of the brand against FDA’s live warning-letter datatable with both controls green.
- Re-fetched the letter: 200, with a title matching the brand, the reference number and the issue date, against a minted nonsense letter path returning a 404 in the same run.